Metastatic Prostate Cancer Medications

Page updated Winter 2021.

Disclaimer: Medicine is an ever-changing science. We have been witnessing changes in diagnostic and therapeutic modalities and guidelines during last several years. We have used sources believe to be reliable for purpose of this website including AUA guidelines, EAU guidelines, NCCN guidelines, Campbell-Walsh-Wein Urology, UpToDate, Merck Manual, Lexi-Comp, FDA website, and other reputable sources. However, due to possibility of human error or changes in medicine, readers are required to confirm the information provided in this website with other sources. Readers are specially required to read all parts of the product information sheet included in the package of each drug they plan to administer and follow those instructions. Readers are also needed to follow instructions of FDA and other regulatory bodies and their own department in this regard. Authors can cite information provided in our textbooks or they need to cite the original sources. This website serves as a general framework. We and other users would adjust the approach per departments policies and patients situation. Forms can be used by other health care professionals.

LHRH Agonists


Leuprolide (Lupron)


7.5 mg IM for 1-Month


22.5 mg IM for 3-Months


30 mg IM for 4-Months


45 mg IM for 6-Months


Leuprolide (Eligard)


Same dose as above, SC


Goserelin (Zoladex)


3.6 mg SC- for 1-Month


10.8 mg SC- for 3-Months


Triptorelin (Trelstar)


3.75 mg IM for 1 Month


11.25 mg IM for 3 Months


22.5 mg IM for 6 Months


LHRH Antagonists


Degarelix (Firmagon)


Initial dose: 240 SC in 2 divided dose


Then : 80 mg SC every 28 days


Abarelix (Plenaxis)


100 mg administered intramuscularly to the buttock on day 1, 15, 29 (week 4) and every 4 weeks thereafter.


Non-steroidal Anti-androgens


Bicalutamide (Casodex)


50 mg PO daily for 4 weeks to block LHRH agonists flare-up phenomenon.


Flutamide (Eulexin)


250 mg PO q8hr for 4 weeks to block LHRH agonists flare-up phenomenon.


Nilutamide (Nilandron)


300 mg PO daily for 4 wks to block LHRH agonists flare-up phenomenon.


Androgen Synthesis Inhibitors


Abirateron (Zytiga)


1000 mg PO daily


Add Prednisone 5 mg PO q12hr


Second-Generation Androgen Receptor Antagonists


Enzalutamide (Xtandi)


160 mg PO, daily


Apalutamide (Erleada)


240 mg PO, daily


Chemotherapy Agents


Docetaxel (Taxotere)


75 mg/m2 IV over 1 hr q3 Weeks


Add Prednisone 5 mg PO q12hr


Cabazitaxel (Jevtana)


20 mg/m2 IV over 1 hr q3 Weeks


Add Prednisone 10 mg PO q Day


Immunotherapy


Sipuleucel-T (Provenge)


3 doses (>50 million autologous CD54+ activated cells/dose) IV over 60 min at approximately 2-week intervals


Pembrolizumab (Keytruda)


200 mg IV q3 Weeks OR 400 mg q6 Weeks OR 400 mg q6 Weeks until disease progression, unacceptable toxicity, or up to 24 months without disease progression.


Radiopharmaceuticals


Radium-223 (Xofigo)


50 kBq (1.35 microcurie) per kg body weight, IV, given at 4 week intervals for 6 injections.



Prostate Cancer Bone Health


Calcium


1000-1200 mg per day


Vitamin D


1000 IU


Zoledronic acid (Zometa, Reclast):


Osteoporosis-related fracture prevention:


Reclast


5 mg IV over >15 minutes every year


Bone metastasis from solid tumors:


Zometa


4 mg as a single-use intravenous infusion over > 15 minutes every 3-4 weeks for patients with creatinine clearance of greater than 60 mL/min.


Denosumab (Prolia, Xgeva):


Androgen deprivation induced bone loss:


Prolia


60 mg SC q6months


Bone metastasis from solid tumors:


Xgeva


120 mg SC q4Weeks


Treatment Options for Bothersome Hot Flashes


Megestrol acetate


20 mg, twice per day. Can be reduced to 5 mg bid


Cyproterone acetate


Start at 50 mg/day. May be titrated to 300 mg/day


Venlafaxine


12.5 mg, twice daily


Gabapentin


900 mg daily (300 mg TID).Start with 300 and get to 900 mg on day 3